Product logins

Find logins to all Clarivate products below.


Sickle Cell Disease | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2016

Sickle cell disease (SCD) is a genetic disorder characterized by abnormality in the oxygen-carrying protein hemoglobin. The gene mutation underlying the disease results in the amino acid valine replacing glutamic acid at the sixth position of hemoglobin’s β globin chain, leading to hemoglobin polymerization, which causes red blood cells (RBCs) to become distorted into a sickle shape. The sickled, adherent RBCs are at the basis of a series of downstream complications such as vaso-occlusion (VOC) associated with pain attacks, acute chest syndrome, and anemia. Hematopoietic stem cell transplantation is the only cure for SCD, but its use is limited to a small portion of patients. Prophylactic penicillin to prevent commonly occurring infections, analgesics for pain episodes, hydroxyurea to increase the expression of an alternative form of hemoglobin, and blood transfusions are the cornerstones of SCD management. These therapeutic options help control acute and chronic complications associated with SCD and improve patients’ quality of life, but the use of hydroxyurea and blood transfusions in particular can be burdensome. Hydroxyurea actually is a therapy targeting the underlying cause of SCD, but it is associated with safety concerns and frequent blood count monitoring. Chronic transfusion requires periodic evaluations of iron overload, liver function, serum ferritin, and hepatitis B and C and HIV infection. The unmet needs are high for therapies that can reduce the duration of VOC and therapies that target the underlying cause of the disease. ​

Related Market Assessment Reports

Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…